The abstract is read at the publisher; the summary is JClub's.
A modified long-acting acylated UCN2 peptide reduces fat mass while preserving skeletal muscle mass and function in multiple mouse models, with benefits persisting 4 weeks after dosing stops.
- Why it matters: No approved pharmacotherapy both lowers excess adiposity and maintains skeletal muscle quality, limiting treatment of pharmacological weight loss and sarcopenic obesity.
- What they did: In mice, the team tested UCN2 versus pair-feeding and in combination with semaglutide or retatrutide, measuring lean/muscle outcomes, in vivo force, energy expenditure, and fatty acid oxidation.
- The result: UCN2’s fat loss was independent of reduced food intake, increased energy expenditure, prevented adaptive expenditure decline, and in sarcopenic obese mice increased muscle mass, function, and myofibrillar protein synthesis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.